Axogen Launches New Product to Aid Nerve Healing: Avive+ Soft Tissue Matrix
Axogen Launches New Product to Aid Nerve Healing: Avive+ Soft Tissue Matrix
Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announces the launch of its newest product, Avive+ Soft Tissue Matrix. Avive+ is intended for use as a soft tissue barrier and is a resorbable, multi-layer amniotic membrane allograft that provides temporary protection and tissue separation during the critical phase of peripheral nerve healing. Avive+ is processed and distributed in accordance with U.S. Food and Drug Administration (FDA) requirements for Human Cellular and Tissue-based Products (HCT/P) under 21 CFR Part 1271 regulations, U.S. State regulations as a 361 human tissue product.
全球領先的外周神經損傷手術解決方案開發和推廣廠商納斯達克(AXGN)的Axogen公司宣佈推出其最新產品Avive+軟組織基質。Avive+旨在用作軟組織屏障,是一種可吸收的多層羊膜異體移植物,可在外周神經癒合的關鍵階段提供臨時保護和組織分離。符合美國食品和藥物管理局(FDA)人類細胞和組織製品(HCT/P)21 CFR第1271條規定以及美國州立規定的要求的處理和分發。
"Product innovation is integral to our mission at Axogen," stated Karen Zaderej, Chairman, CEO, and President. "With the introduction of Avive+ Soft Tissue Matrix, we are excited to enhance our comprehensive solutions for nerve protection and address a significant need for patients with compression or non-transected nerve injuries."
Axogen公司的主席、首席執行官和總裁Karen Zaderej指出:"產品創新是我們在Axogen的使命中非常重要的一部分。通過推出Avive+軟組織基質,我們很高興爲神經保護提供全方位的解決方案,滿足壓迫性或非斷裂神經損傷患者的重大需求。"
Nerve protection represents approximately $800 million of the overall nerve repair market and covers a wide range of injuries and defects including carpal and cubital tunnel syndromes, crush injuries, and other non-transected traumatic nerve injuries. The diversity of these injury types and their anatomical locations present unique challenges and Axogen is committed to optimizing outcomes for patients, using its targeted portfolio of solutions to address the needs of each injury type, and the healing process. Avive+ Soft Tissue Matrix complements the Company's existing portfolio of nerve protection products, which includes Axoguard Nerve Protector and Axoguard HA+ Nerve Protector.
神經保護佔據了整個神經修復市場約8億美元的份額,包括腕隧道綜合症、肘隧道綜合症、擠壓傷和其他非斷裂創傷性神經損傷以及缺陷等各種損傷類型和其不同的解剖位置,因此具有獨特的挑戰。Axogen致力於通過其有針對性的解決方案組合來滿足每種損傷類型和癒合過程的需求,以優化患者的康復療效。Avive+軟組織基質使其神經保護產品系列更加完善,包括Axoguard神經保護器和Axoguard HA+神經保護器。